×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Experiment: TREM2 Agonist Therapy for Parkinson's Disease — Experimental
experiment
707 words
Contents
TREM2 Agonist Therapy for Parkinson's Disease — Experimental Design
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (27)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
APOE-TREM2 Interaction Modulation
Score: 0.74
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
TREM2-Dependent Microglial Senescence Transition
Score: 0.58
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.90
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.75
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
PARP1 Inhibition Therapy
Score: 0.74
CYP46A1 Overexpression Gene Therapy
Score: 0.73
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69
pg 1/2
Next →
Related Analyses (30)
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · completed
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
What are the optimal timing windows for TREM2 agonism vs ant
neurodegeneration · archived
Does SYK activation provide neuroprotection or exacerbate ne
neurodegeneration · archived
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Neuroinflammation and microglial priming in early AD
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Show 25 more
Related Experiments (30)
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · in_progress · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40
Microglial Aging and Immune Memory in Neurodegeneration — Tr
validation · proposed · Score: 0.40
Microglial Contributions to Huntington's Disease Pathogenesi
validation · proposed · Score: 0.40
Mixed Pathology Effects on Parkinson's Disease Progression a
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
Prodromal Parkinson's Disease Biomarker Development — Early
clinical · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
DLB Cognitive Fluctuation Mechanism Experiment
clinical · proposed · Score: 0.40
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40
Genetic Risk Modifiers in DLB Phenotype
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
s:** - Compare tau strain spreading in EXT1/EXT2 conditional
falsification · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
s:** - GPR32 knockout in microglia should worsen neuroinflam
falsification · proposed · Score: 0.40
Show 25 more
See Also (15)
sTREM2 (Soluble TREM2) - Biomarker
biomarker · Pages share 4 hypotheses
al002-trem2-agonist-alzheimers
clinical_trial · Pages share 4 hypotheses
TREM2 Gene
gene · Pages share 4 hypotheses
sTREM2 (Soluble TREM2) - Microglial Biomarker
biomarker · Pages share 4 hypotheses
TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk
mechanism · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 3 hypotheses
Rotigotine and Rivastigmine Combination Therapy for Alz
clinical · Pages share 3 hypotheses
LEAF Trial - THC+CBD for Alzheimer's Disease Agitation
clinical · Pages share 3 hypotheses
NCT07262645: Near-Infrared Light Therapy for Mild-Moder
clinical_trial · Pages share 3 hypotheses
Master Screening Study to Determine Individuals With Po
clinical · Pages share 3 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 3 hypotheses
The Alzheimer's Disease Tau Platform Clinical Trial (NC
clinical · Pages share 3 hypotheses
Antibody Therapy in Neurodegeneration
mechanism · Pages share 3 hypotheses
APOE Lipid Metabolism Pathway in Alzheimer's Disease
mechanism · Pages share 3 hypotheses
EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzh
clinical · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (8 edges)
TREM2
regulates
Amyotrophic Lateral Sclerosis
TREM2
activates
Neurodegeneration
TREM2
regulates
Multiple Sclerosis
TREM2
activates
Als
TREM2
regulates
Alzheimer
TREM2
regulates
Ms
TREM2
regulates
Phagocytosis
TREM2
activates
PI3K/AKT PATHWAY
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.